For research use only. Not for use in humans.

Garetosmab (Anti-INHBA / Activin A)

Synonyms: Activin A, INHBA

Garetosmab (Anti-INHBA / Activin A) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research. MW: 145.5 kD.

Garetosmab (Anti-INHBA / Activin A)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Specificity

Name Citation ALK1 ALK2 ALK3 ALK4 TGFβRI/ALK5 ALK6 TGFβRII TGF-β Smad3 ALK7 Others
SB431542 826
LDN-193189 278
Galunisertib (LY2157299) 193
LY2109761 138
SB-525334 120
SB505124 37
GW788388 26
LY364947 49 RIPK2,CK1δ,MLK-7K
RepSox (E-616452) 86
LDN-193189 Dihydrochloride 108
K02288 25
TGFβRI-IN-3 2
R-268712 1
BIBF-0775 0
TP0427736 HCl 6
A-83-01 75
LDN-214117 4
SD-208 23
Vactosertib (TEW-7197) 29
ML347 5
LDN-212854 8
DMH1 63
Dorsomorphin Dihydrochloride 515 AMPK
PF-06952229 0
Ginsenoside Rh4 0
SIS3 17
AUDA 1 TNF-α,IL-1β,MMP-9
PD 169316 2 Activin A,Enterovirus71,p38 MAPK
TA-02 0 p38 MAPK
ITD-1 15
LY 3200882 7
Alantolactone 3 STAT3
Halofuginone 13 prolyl-tRNA synthetase
SIS3 Hydrochloride 86
Dorsomorphin (Compound C) 478 AMPK
Hesperetin 4 Histamine receptor
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Garetosmab (Anti-INHBA / Activin A) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research. MW: 145.5 kD.

Product Details

CAS No. 2097125-54-5
Molecular Weight 145.5 kDa
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07559513 NOT_YET_RECRUITING Drug: garetosmab Fibrodysplasia Ossificans Progressiva (FOP) Regeneron Pharmaceuticals 2027-02-02 PHASE3
NCT06299098 ACTIVE_NOT_RECRUITING Drug: Trevogrumab-Part A|Drug: Trevogrumab-Part B and Part C Obesity Regeneron Pharmaceuticals 2024-03-13 PHASE2
NCT06970405 WITHDRAWN Drug: Garetosmab|Drug: Matching Placebo Obesity Regeneron Pharmaceuticals 2025-05-29 PHASE1
NCT07253363 ACTIVE_NOT_RECRUITING Pulmonary Hypertension Assistance Publique - Hôpitaux de Paris 2024-03-01
NCT05394116 ACTIVE_NOT_RECRUITING Drug: Garetosmab|Drug: Placebo Fibrodysplasia Ossificans Progressiva Regeneron Pharmaceuticals 2022-11-21 PHASE3
NCT04577820 WITHDRAWN Drug: garetosmab Fibrodyplasia Ossificans Progressiva (FOP); Heterotopic Ossification (HO) Regeneron Pharmaceuticals 2021-10-13 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-08-24)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.